UCal further strengthens CRISPR position in Europe, but Cas9 licensing situation remains tricky
EPO Opposition Division upholds another key Doudna patent, but several gene-editing appeals are still in play
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.